+34 620 10 75 37info@nanbiosis.com

Posts by Nanbiosis

You are here : Home / Articles by Nanbiosis (Page 79)

NANOMOL group, coorditator of Unit 6 of NANBIOSIS has authored 26% of the scientific articles of ICMAB in NATURE

The Nature Index takes into account the published scientific articles from 1 February 2016 to 31 January 2017.  This index is elaborated annually based on the affiliations of the authors of scientific articles published in a selection of 68 high-quality journals (http://www.natureindex.com/faq#journals)

CSIC appears as the first Spanish research centre in this ranking and occupies position number 38 in the global ranking of 500 research centres worldwide, while ICMAB occupies the first position within the CSIC centre, taking into account the corrected index WFC that shares the work between the different co-authoring institutions and corrects for the overrepresentation of some fields. Thus, ICMAB appears in the Nature index with a total of 42 articles out of which 12 have been authored by researchers of NANOMOL, showing a significant contribution (26% of the publications contained in this list) to the leadership of ICMAB in excellence in Science.

Some of the published papers were made taking advantage of the characterization facilities provided by ICTS NANBIOSIS

NANOMOL is a research group with wide expertise and recognized excellence in the synthesis, processing and study of molecular and polymeric materials with chemical, electronic, magnetic and biomedical properties, that continuously generate new knowledge in its basic and applied research projects regarding the micro and nano structuring of molecular materials. NANOMOL offers this knowledge to improve the properties of products manufactured in diverse sectors, such as chemicals, pharmaceuticals and electronics, thereby contributing to increasing their added value. NANOMOL is a research group actively involved in implementing nanotechnology and sustainable and economically efficient technologies for preparing advanced functional molecular materials. It is also the group coordinator of Unit 6 of NANBIOSIS and its Leader group, Dr. Jaume Veciana, is the Scientific Director of NANBIOSIS-ICTS

• Read More

JUMISC awarded with the Prize to the Best Research Practice

Last Friday, May 5, JUMISC was awarded in the 1st edition of Extremadura Health Prices, event organised by Sanitaria 2000, text-editor of the Redacción Médica, the most famous and specialised newspaper in its sector.

The contribution of the Extremadura Health Service and the regional health sector were awarded between the 56 nominations included in 14 categories. JUMISC obtained the award of “Best Research Practice”.

The event was held in the convent of San Juan de Dios, in Olivenza-Badajoz, and gathered the JUMISC’s Scientific Director, Mr. Sánchez Margallo (on behalf of the institution),  together with other authorities and health managers.

A prestigious jury decided about winners in accordance to the following classification: The best public hospital, the best hospital service, the best physician, the best primary healthcare, the best health administration, the best research practice, the best private health institution, the best nursery practice, the best social responsibility for health, the best scientific society, the best technological contribution, the best association of patients and the best chemistry practice.

• Read More

New sensor for quick and easy detection of ecstasy

Spanish, Danes and Austrian researchers, including the group led by Ramón Martínez Mánez, coordinator of Unit 26 of NANBIOSIS, have developed a new sensor to detect ecstasy in a simple, reliable, fast and selective way.

Until now, this drug is detected by techniques such as capillary electrophoresis, spectroscopy or chromatography that require the use of expensive technical equipment and qualified personnel. The new method offers the advantages of easy use, low cost and high reliability according to Beatriz Lozano, a researcher at the Interuniversity Institute for Research on Molecular Recognition and Technological Development at the Universitat Politècnica de València and the group led by Ramón Martínez Mañez.

The sensor consists of a hybrid material including an inorganic carrier charged with a dye -fluorescein- and functionalized with an organic molecule derived from naphthol.

The dye is retained when the bluebox-molecule widely used in chemistry- is coordinated to the naphthol forming a molecular gate and in the presence of ecstasy in the analyzed sample, a variation of the fluorescence occurs, whose intensity varies as a function of the concentration of Drug detected.

“The affinity of BlueBox for different neurotransmitters such as dopamine had already been described, and because of the structural similarity between that neurotransmitter and ecstasy, we thought it would be a good idea to try to open the “molecular gate” in the presence of the drug and release the dye that gives the fluorogenic response”, explains Beatriz Lozano.

The characterization of the products by NMR was carried out by using facilities from NANBIOSIS-ICTS (unit 26)

Researchers are currently working on a new sensor for the detection of other synthetic drugs.

Reference Article:

Beatriz Lozano-Torres, Lluís Pascual, Andrea Bernardos, María D. Marcos, Jan O. Jeppesen, Yolanda Salinas, Ramón Martínez-Máñez and Felix Sancenón. Pseudorotaxane capped mesoporous silica nanoparticles for 3,4-methylenedioxymethamphetamine (MDMA) in water detection. Chem. Commun., 2017, 53, 3559. DOI: 10.1039 / C7CC00186J

• Read More

2nd SUMMER SCHOOL OF EUROPEAN AND INTERNATIONAL SOCIETIES FOR NANOMEDICINE (ESNAM/ISNM)

The ESNAM / ISNM Summer School is co-organized by ESNAM and CIBER-BBN (led by Simó Schwartz, president of ESNAN and transfer manager of CIBER-BBN as well as Scientific Director of Unit 20 of NANBIOSIS).

The summer school is aimed at any student or professional interested in nanomedicine. It will count on the presence of speakers of recognized prestige in the area, among which are the Scientific Directors and Coordinators of several of the units of NANBIOSIS.

The ESNAM / ISNM Summer School will be held on 28-29 September 2017 at the Hospital Vall d’Hebron, Barcelona

The registration deadline with accommodation included ends on June 30

Program and registration details

• Read More

Laura Lechuga in the fight against cancer

Dr. Laura Lechuga, Scientific Director of Unit 4 of NANBIOSIS is highlighted in Cinco Días. Elpais Economía  for its fight against cancer and, in particular, for the device developed with its team to detect the disease in matter of minutes

“Have you ever wondered why glucose meters are so smart that they just measure sugar? The answer is that they carry specific proteins that only interact with sugar, “explains the doctor.  The same idea lies in the device designed by Laura Lechuga and her research group “With a minimum sample of the patient, it is possible to detect the presence of different diseases depending on the protein located in the micro-receiver, in an economic and fast way”.

Due to these characteristics, this developed technology, has great potential for greatly improving health in underdeveloped countries, as well as in other fields like measure the presence of pollutants or toxic agents in the environment.

In the news published by Cinco Días. Elpais Economía other scientists in the fight against cancer are interviewed, as Angel Raya (from CIBER-BBN) about the regenerative medicine.

More information here

• Read More

NANBIOSIS Scientific Director Dr. Jaume Veciana received a Mention of Honor for his dedication to NANBIOSIS

On April 22, Dr. Jaume Veciana received a Mention of Honor from the current President of Extremadura, Guillermo Fernández Vara, during the celebration of the X Anniversary of the Center for Minimally Invasive Surgery “Jesus Usón” for his commitment, effort and dedication in the creation of the Singular Scientific Technological Infrastructures (ICTS) NANBIOSIS, in collaboration with the Center for Biomedical Research Center in Bioingeneering, Biomaterials and Nanomedicine (CIBER-BBN).

Further information:

• Read More

J. Santamaría, U9 NANBIOSIS gets 2.5M € to develop a revolutionary cancer treatment

Jesús Santamaría, Scientific Director of Unit 9 of NANBIOSIS, has obtained, for the second time in six years, an ERC Advanced Grant, one of the most prestigious and extremely competitive European research grants, restricted to senior researchers with a research trajectory of high quality for more than ten years.

The CADENCE (Catalytic Dual-Function Devices Against Cancer) project will be financed by the EU with 2.5M € to work for five years with a powerful team: four own researchers and seven others to be selected from candidates from all over the world.

With this project the researchers propose a revolutionary cancer treatment to be developed and tested. “The central idea of ​​the project is to consider the tumor as a chemical reactor in which catalysts can be introduced. A catalyst is agent  capable of directing chemical reactions and, in this case, would destroy molecules that are useful for the tumor and generate toxic products inside the tumor. The project thus has the potential to add a new member -catalysis- to the toolbox in oncology And if we could do within the tumor cells themselves we would have a very powerful tool. It would be to use catalysis as an arsenal in oncology “,  explained Jesús Santamaría.  But in addition to developing catalysts that can work successfully under intratumoral conditions (temperature, oxygen concentration, pH), a method must be devised to bring those catalysts selectively into the tumor either through the capillaries by which it extends or Or inside mesenchymal stem cells, as a Trojan horse. Finally, the project contemplates activating the catalysts remotely by infrared radiation, once they have achieved their goal. There are already initial results of the group that allow to glimpse possibilities of achieving these three objectives. A central part of the project will be the synthesis of catalytic nanomaterials. For this, the capabilities of NANBIOSIS-ICTS will be intensely used”

Jesús Santamaría, believes that CADENCE has been selected because it is a new idea and, a priori, could be used in all types of tumors. “It’s new, it’s interesting and we’re going to contract the best researchers, because we’re going to need them,” he said. Among others, they will need experts in oncology, in photocatalysis and in modulation of bioreactors.  .

• Read More

10th Anniversary of the New Minimally Invasive Surgery Centre (JUMISC)

Next Friday, 21st April, we celebrate the 10th Anniversary of the new JUMISC, betting on training and on research and development activities. 

In its ten years of background we emphasize the following figures:

  • 500 trained physicians,
  • 160 training activities per year
  • More than 100 R&D projects with 7.930.800 € funding
  • 17 patents,
  • The creation of a spin-off,
  • The development of 25 apps,
  • More than 623 scientific collaborators,
  • 500 visits received from more than 500 institutions.

10 years full of training courses and European R&D projects. We are so proud for  the promotion and creation of the  Clúster Sociosanitario of Extremadura (Health Cluster), for obtaining the Good Laboratory Practice to  carry out preclinical trials, for launching a Program of training on Assisted Reproduction, for creating a 3D Department to develop apps, for being included as ICTS in the Spanish Map of Singular Facilities and in the CIBER-CV (Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares).

Jesus Usón Minimally Invasive Surgery Centre (JUMISC), one of NANBIOSIS partners together with CIBER-BBN, is a multidisciplinary institution devoted to research and innovation in health sciences.

Further info about our achievement in:

http://10aniversario.ccmijesususon.com/

• Read More

New treatments for degenerative diseases of the retina

The final meeting of the TERET project took place last March, an initiative within the RETOS public-private collaboration initiative of the Ministry of Economy, Industry and Competitiveness funded with almost € 1 million. The project has been carried out over the past three years to develop new treatments for degenerative diseases of the retina, focusing specifically on age-related macular degeneration (AMD), diabetic retinopathy ( RD) and retinitis pigmentosa.

Unit 10 of ICTS NANBIOSIS has participated in carrying out the pharmaceutical formulation of the active principles, including the synthesis, chemical physical characterization and stability of the formulations over time, evaluation of the silencing capacity and viability of the formulations used in cellulare crops, together with the CIBER-BBN groups led by José Luis Pedraz (University of the Basque Country), Ramon Eritja (IQAC-CSIC) and Eduardo Fernández (U. Miguel Hernández de Elche) and the biotechnology companies Sylentis , LeadArtis and Leitat.

Gene silencing solutions have been used as a basis for this project through the use of interfering RNA (siRNA) nd multivalent antibodies in Trimerbody format.

• Read More

Unit 2 Nanbiosis have signed an agreement with a Belgian Enterprise.

U2 unit of Nanbiosis (Custom antibody service) has recently signed a 3-year contract with UNISENSOR S.A. (Liege, Belgium) for producing on a high scale a collection of immunoreagents used in their diagnostic kits.

UNISENSOR S.A. is a SME biotech company that develops on site diagnostic systems for food safety. Unit 2 of NANBIOSIS, coordinated by Nb4D-CSIC holds a research collaboration for more than 7 years developing new bioproducts and transferring knowledge to UNISENSOR S.A. As result of the collaboration several diagnostic kits are nowadays in the market, consequently this contract has been signed with the aim to supply UNISENSOR S.A. with immunoreagents for their diagnostic products. The biomolecules produced by CAbS are completely characterized and respond to quality control criteria required by UNISENSOR S.A.

• Read More